Exelixis (EXEL) hit the lower rail of its upward sloped trend channel ahead of earnings
Biotech firm Exelixis (Nasdaq: EXEL) has been trending higher since the end of October. There have been cycles within the overall upward trend and those cycles have created a trend channel. The lows from October and December connect to form the lower rail. The highs from November and January connect to form the upper rail. The stock hit the lower rail of the channel on February 8 and that was just ahead of the company’s earnings report on February 12.
The oscillators were both low with the 10-day RSI close to oversold territory and the daily stochastic readings were in oversold territory. The stochastic readings just made a bullish crossover at the close on the 12th. That pattern looks similar to what we saw at the end of December.
Tickeron’s A.I. Trend Prediction tool generated a bullish signal on Exelixis on February 11. That prediction showed a confidence level of 85% for a move of 4% or more within the next month and 86% of the predictions of this kind have been successful in the past.
The company reported earnings after the close on February 12 and the results were better than analysts’ estimates. The company earned $0.37 per share which beat the consensus estimate of $0.25. Exelixis reported revenue of $228.6 million and that beat the estimate of $195.7 million.
Exelixis has seen its sales grow at a rate of 212% per year over the last three years. Earnings grew by 208% in the quarter and sales were up 48%. The company boasts a return on equity of 82.4% and a profit margin of 35%. It is also worth noting that the company doesn’t have any long-term debt.
EXEL's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for EXEL moved out of overbought territory on July 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 instances where the indicator moved out of the overbought zone. In of the 44 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 73 cases where EXEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EXEL broke above its upper Bollinger Band on July 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 295 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.143) is normal, around the industry mean (20.302). P/E Ratio (18.214) is within average values for comparable stocks, (37.580). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (2.487). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.406) is also within normal values, averaging (395.736).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
Advertisement